Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.42)
# 966
Out of 5,055 analysts
83
Total ratings
46.07%
Success rate
5.51%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRMD CorMedix | Maintains: Buy | $17 → $18 | $9.98 | +80.36% | 4 | Nov 13, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $44 → $46 | $45.34 | +1.46% | 7 | Nov 7, 2025 | |
| INDV Indivior | Maintains: Buy | $28 → $35 | $31.38 | +11.54% | 2 | Oct 30, 2025 | |
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.94 | +467.01% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $9.08 | +120.26% | 3 | Oct 15, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $4.98 | +120.88% | 6 | Oct 13, 2025 | |
| GNFT Genfit | Maintains: Buy | $9 → $7 | $4.61 | +51.84% | 2 | Sep 24, 2025 | |
| RNTX Rein Therapeutics | Initiates: Buy | $10 | $1.22 | +719.67% | 1 | Sep 22, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $93 → $121 | $81.97 | +47.61% | 6 | Sep 17, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $18 | $8.89 | +102.47% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.69 | +69.05% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.40 | +172.73% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.60 | +81.82% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.64 | +257.63% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.49 | +181.12% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $7.26 | +37.74% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $7.81 | +271.32% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $12.82 | +56.01% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.18 | +183.22% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.09 | +450.46% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $2.32 | +115.52% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.98 | +818.37% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $11.35 | +85.02% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.87 | +477.63% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.31 | +2,475.66% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $10.10 | +58.42% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $15.51 | +2,833.59% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $21.07 | +180.02% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $170.09 | +5.83% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.54 | +8,561.42% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.33 | +9.10% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.04 | +2,115,284.62% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $8.27 | +504.59% | 1 | Jul 12, 2018 |
CorMedix
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $9.98
Upside: +80.36%
Collegium Pharmaceutical
Nov 7, 2025
Maintains: Buy
Price Target: $44 → $46
Current: $45.34
Upside: +1.46%
Indivior
Oct 30, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $31.38
Upside: +11.54%
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.94
Upside: +467.01%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $9.08
Upside: +120.26%
MannKind
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $4.98
Upside: +120.88%
Genfit
Sep 24, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $4.61
Upside: +51.84%
Rein Therapeutics
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.22
Upside: +719.67%
ANI Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $81.97
Upside: +47.61%
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $8.89
Upside: +102.47%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.69
Upside: +69.05%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.40
Upside: +172.73%
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $6.60
Upside: +81.82%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.64
Upside: +257.63%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.49
Upside: +181.12%
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $7.26
Upside: +37.74%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $7.81
Upside: +271.32%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $12.82
Upside: +56.01%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.18
Upside: +183.22%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.09
Upside: +450.46%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $2.32
Upside: +115.52%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $0.98
Upside: +818.37%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $11.35
Upside: +85.02%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.87
Upside: +477.63%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.31
Upside: +2,475.66%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $10.10
Upside: +58.42%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $15.51
Upside: +2,833.59%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $21.07
Upside: +180.02%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $170.09
Upside: +5.83%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.54
Upside: +8,561.42%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.33
Upside: +9.10%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.04
Upside: +2,115,284.62%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $8.27
Upside: +504.59%